List of Excipients in Branded Drug NEO-POLYCIN

« Back to Dashboard

Generic Drugs Containing NEO-POLYCIN

Company	Ingredient	NDC	Excipient
Rebel Distributors Corp	neomycin and polymyxin b sulfates and bacitracin zinc	42254-302	MINERAL OIL
Rebel Distributors Corp	neomycin and polymyxin b sulfates and bacitracin zinc	42254-302	PETROLATUM

What are the Most Frequently-Used Excipients in NEO-POLYCIN?

# Of NDCs	Excipient
1	MINERAL OIL
1	PETROLATUM

NEO-POLYCIN Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

NEO-POLYCIN is a sterile ophthalmic ointment combining bacitracin zinc, neomycin sulfate, and polymyxin B sulfate. Its commercial proposition is based on broad topical antibacterial coverage, ocular tolerability, sterile manufacturing, and access to the established ophthalmic antibiotic market. The core excipient platform is mineral oil and white petrolatum, which provides an anhydrous ointment base and supports preservative-free packaging. The strongest commercial opportunities are differentiated delivery formats, improved patient usability, private-label supply, and lifecycle extensions rather than new active-ingredient claims.

What is NEO-POLYCIN and which excipients does it contain?

NEO-POLYCIN ophthalmic ointment contains three antibacterial active ingredients:

Component	Function
Bacitracin zinc	Gram-positive antibacterial activity
Neomycin sulfate	Aminoglycoside antibacterial activity
Polymyxin B sulfate	Activity against susceptible Gram-negative organisms

The U.S. prescribing information identifies mineral oil and white petrolatum as inactive ingredients in the ophthalmic ointment formulation.[1] The formulation is an anhydrous, sterile ophthalmic base. It does not require an aqueous preservative system, which is commercially relevant for ocular-surface tolerability and preservative-free positioning.

NEO-POLYCIN is distinct from NEO-POLYCIN HC, which adds hydrocortisone and therefore creates a separate regulatory, clinical, labeling, and safety profile. The excipient analysis below concerns the antibacterial ointment unless otherwise stated.

How does the NEO-POLYCIN excipient system work?

The excipient system performs four primary functions:

1. It suspends or distributes the active ingredients in a semisolid ophthalmic vehicle.
2. It provides residence time on the ocular surface.
3. It limits water activity and supports chemical stability.
4. It permits sterile filling into ophthalmic tubes.

White petrolatum

White petrolatum is the principal occlusive and structuring component. It creates a cohesive ointment matrix and supports prolonged retention after administration. Its limitations include temporary blurred vision, patient perception of greasiness, and variable extrusion force depending on tube geometry, storage temperature, and manufacturing history.

Mineral oil

Mineral oil reduces the stiffness of petrolatum and improves spreadability. Its concentration and viscosity influence:

• Ointment consistency
• Extrusion force
• Melting and softening behavior
• Ocular residence time
• Patient perception of residue
• Homogeneity of active distribution

A lower-viscosity mineral-oil system may improve handling but can increase migration, leakage, and dose variability. A higher-viscosity system may improve retention but worsen patient acceptance.

Absence of aqueous excipients

The anhydrous base avoids several problems associated with water-containing ophthalmic formulations, including microbial proliferation, hydrolysis, and preservative exposure. It also increases the importance of:

• Active-particle deagglomeration
• Uniform content distribution
• Control of water ingress during manufacturing
• Compatibility between active salts and the hydrocarbon base
• Sterility assurance for the finished product

What formulation patents could protect a NEO-POLYCIN lifecycle product?

A reformulated NEO-POLYCIN product would require a patent strategy directed at the delivery system, manufacturing process, or patient-use benefit. The legacy active combination itself is unlikely to provide meaningful new-product exclusivity because bacitracin, neomycin, and polymyxin B are long-established antibacterial agents.

Potential claim areas include:

Patent area	Potential claim subject	Commercial value
Ointment rheology	Defined mineral oil-to-petrolatum ratio, viscosity, yield stress, or extrusion profile	Moderate
Particle engineering	Reduced agglomeration or controlled particle-size distribution	Moderate
Sterile manufacturing	Aseptic or terminal-sterilization process compatible with the actives	Moderate to high
Packaging	Low-residual, unit-dose, preservative-free delivery system	High
Drug delivery	Improved ocular retention with reduced visual blurring	High
Stability	Extended shelf life under defined temperature and humidity conditions	Moderate
Combination product	Specific active-to-excipient ratios linked to dose uniformity or tolerability	Moderate
Patient-use method	Administration regimen or postoperative use	Low to moderate

A patent application would need to claim measurable technical properties rather than simply substitute one grade of petrolatum for another. Stronger claims would link the excipient architecture to a demonstrated benefit, such as lower force-to-extrude, improved content uniformity, reduced particle sedimentation, reduced ocular blur, or longer stability.

What formulation improvements could create commercial differentiation?

Lower-blur ophthalmic ointment

The principal weakness of ophthalmic ointments is transient visual impairment. A lower-blur version could use a narrower rheology profile, lower-residue hydrocarbons, or a structured lipid system that maintains ocular retention while reducing the optical film.

Commercial positioning could include:

• Nighttime use
• Postoperative prophylaxis
• Pediatric administration
• Patients who cannot tolerate drops
• Hospital and ambulatory surgery center protocols

The development challenge is proving that lower visual blur does not materially reduce residence time or antibacterial exposure.

Unit-dose preservative-free packaging

A single-use tube or ampule could differentiate NEO-POLYCIN from multidose products. The opportunity is strongest where clinicians want to minimize contamination risk or avoid repeated tube handling.

A unit-dose product would require optimization of:

• Fill weight
• Delivery aperture
• Residual volume
• Container closure integrity
• Sterility through shelf life
• Patient ability to dispense the complete dose

The packaging could support a premium price if it reduces waste and contamination concerns. The tradeoff is higher packaging cost and more complex filling operations.

Improved extrusion and dose control

Ophthalmic ointments can deliver variable amounts because patients apply different pressures to the tube. A formulation and package combination could target consistent strip length or mass per actuation.

Useful development metrics include:

• Extrusion force at refrigerated, room, and elevated temperatures
• Delivered mass per opening
• Strip length variability
• Active content uniformity
• Tube residuals
• Tip occlusion rate

A delivery-control claim is more defensible when tested across multiple tube lots and storage conditions.

Alternative semisolid bases

Potential alternatives include:

• Polyethylene glycol-based ointments
• Silicone-containing systems
• Absorption bases
• Emulsion ointments
• Gel-ointment hybrids
• Bioadhesive polymers

Each alternative changes the regulatory and technical risk profile. Water-containing systems may improve cosmetic feel but introduce preservative, microbial, and active-stability issues. Polyethylene glycol systems may reduce greasiness but can alter ocular tolerability and active release. Silicone systems may improve spreadability but create extractables, compatibility, and cleaning-validation questions.

A reformulator should treat the current mineral oil/white petrolatum system as a benchmark rather than assume that a more complex vehicle will produce a superior product.

What regulatory pathway applies to NEO-POLYCIN reformulation?

In the United States, the regulatory pathway depends on whether the product is a generic equivalent, a line extension, or a clinically differentiated product.

ANDA pathway

An ANDA product would generally need to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. For ophthalmic ointments, relevant considerations include:

• Same active ingredients
• Same dosage form and route
• Equivalent strength
• Comparable inactive-ingredient safety
• Demonstrated sameness or justified differences in excipients
• Sterility
• Comparative physicochemical performance

Excipient differences may be acceptable, but they can trigger additional justification when they affect viscosity, active release, ocular exposure, tolerability, or product performance. FDA’s ophthalmic product guidance emphasizes product quality, sterility, container closure, and comparative performance.[2]

505(b)(2) pathway

A materially different vehicle, delivery system, dosing regimen, or clinical use may be better suited to a 505(b)(2) application. This pathway could support:

• A lower-blur ointment
• A novel unit-dose delivery system
• A new ocular-retention profile
• A different formulation with reliance on published or listed-drug data

The commercial advantage is greater differentiation. The cost is increased regulatory, clinical, and intellectual-property risk.

Drug-device or combination-product considerations

A metered applicator, specialized tube, or single-use dispensing device may create combination-product issues. Device performance would need to be linked to dose delivery, sterility, and user handling. Packaging innovation should be evaluated early because the device may become the principal regulatory constraint.

What is the Orange Book status and exclusivity outlook for NEO-POLYCIN?

NEO-POLYCIN is a legacy antibacterial ophthalmic product. Its commercial protection is unlikely to depend on unexpired compound patents or meaningful new-drug exclusivity. The relevant protection categories are more likely to be:

• Product-specific formulation patents, if any remain in force
• Packaging or device patents
• Manufacturing know-how
• Sterile filling capability
• Customer contracts
• Brand recognition
• Distribution access

An Orange Book review should distinguish NEO-POLYCIN from NEO-POLYCIN HC and from other neomycin, polymyxin B, and bacitracin ophthalmic products. Orange Book listings can change through patent submissions, delistings, product discontinuations, and reference-product updates.[3]

Because the active ingredients are old, a new market entrant should not assume that the absence of an active-ingredient patent eliminates all launch barriers. Formulation, process, and packaging patents can still create litigation risk, although those patents generally provide narrower protection than composition-of-matter claims.

When does NEO-POLYCIN lose exclusivity and what generic entry risks exist?

The principal exclusivity risk is already structural rather than time-dependent. Established antibacterial ophthalmic combinations can face competition from:

• Generic triple-antibiotic ointments
• Separate-component products
• Alternative ophthalmic antibiotic combinations
• Antibiotic-steroid products
• Lower-cost hospital formulations
• Compounded or institutionally sourced products where permitted

A Paragraph IV challenge would be relevant only if an ANDA applicant identified an unexpired Orange Book patent and alleged invalidity, unenforceability, or noninfringement. For a legacy product, greater risk may arise from ordinary ANDA competition after any listed patents expire or are found inapplicable.

Potential generic launch scenarios are:

Scenario	Entry condition	Commercial effect
Standard generic ointment	Same active combination and comparable vehicle	Rapid price pressure
Formulation-different generic	Different excipients with FDA-supported equivalence	Moderate substitution risk
Private-label product	Contract-manufactured equivalent	Increased channel competition
505(b)(2) lower-blur product	Demonstrated usability or performance advantage	Premium segmentation
Unit-dose product	Preservative-free or contamination-reduction positioning	Institutional differentiation

Which companies could compete with or challenge NEO-POLYCIN?

Competition is likely to come from manufacturers with sterile ophthalmic manufacturing and established generic distribution. Relevant competitor categories include:

• Generic ophthalmic manufacturers
• Branded ophthalmology companies
• Contract development and manufacturing organizations
• Hospital-focused sterile-product suppliers
• Retail private-label suppliers

The competitive set includes products containing some or all of the same active ingredients, as well as substitutes such as erythromycin ophthalmic ointment and fluoroquinolone ophthalmic products. Clinical substitution depends on indication, resistance considerations, allergy history, prescriber preference, and whether steroid-containing therapy is appropriate.

Biosimilar competition is not relevant. NEO-POLYCIN is a small-molecule and peptide-antibiotic combination, not a biologic. The relevant competitive pathway is generic substitution, not biosimilar interchangeability.

What licensing and commercial partnership opportunities exist?

The most credible licensing opportunities are formulation and channel-based.

Formulation licensing

A technology owner could license:

• Low-blur ophthalmic ointment technology
• Unit-dose sterile packaging
• Controlled extrusion systems
• Hydrocarbon-base optimization
• Bioadhesive ocular delivery
• Stability-enhancing manufacturing processes

A license is more attractive when it includes comparative performance data, freedom-to-operate analysis, and a scalable manufacturing process.

Manufacturing partnerships

NEO-POLYCIN requires specialized sterile ophthalmic production. A partner with validated ointment compounding, sterile filling, tube sealing, and container-closure testing could offer a faster route to market than internal development.

Key diligence areas include:

• FDA inspection history
• Sterile manufacturing capacity
• Ointment homogenization capability
• Active-substance sourcing
• Tube and nozzle qualification
• Batch-release testing
• Supply continuity for bacitracin zinc, neomycin sulfate, and polymyxin B sulfate

Commercial partnerships

Potential channels include retail pharmacy, ophthalmology distributors, hospitals, ambulatory surgery centers, veterans’ health systems, and private-label pharmacy programs. Institutional buyers may value unit-dose packaging and reliable supply more than incremental cosmetic improvements.

How strong is the NEO-POLYCIN patent estate?

The patent estate should be considered weak for exclusivity based solely on the legacy active combination. The potentially stronger assets are formulation, packaging, and manufacturing patents tied to measurable performance.

Asset category	Expected strength
Active-ingredient composition	Low for new exclusivity
Triple-antibiotic combination	Low to moderate, depending on claim scope and expiration
Hydrocarbon ointment base	Low unless narrowly linked to unexpected performance
Low-blur formulation	Moderate to high if supported by comparative data
Unit-dose sterile package	Moderate
Dose-control applicator	Moderate
Manufacturing process	Moderate, with trade-secret value
Brand and distribution	Commercially meaningful but not patent exclusivity

A defensible lifecycle portfolio would combine narrow formulation claims, package claims, process know-how, trademarks, and regulatory data. A single broad claim covering “an ophthalmic ointment containing mineral oil and petrolatum” would face substantial validity and obviousness risk.

What revenue exposure and commercial upside does NEO-POLYCIN offer?

Publicly reliable product-level revenue data are generally limited for legacy ophthalmic products. Commercial value depends on prescription volume, reimbursement, channel mix, supply reliability, and the degree of generic substitution.

The main revenue risks are:

• Low-cost generic entry
• Declining use of broad-spectrum topical antibiotics
• Neomycin hypersensitivity concerns
• Hospital formulary substitution
• Supply interruptions
• Limited differentiation from other ophthalmic ointments

The main upside opportunities are:

• Premium preservative-free unit-dose packaging
• Contract manufacturing and private-label supply
• Hospital and surgery-center contracts
• Lower-blur administration
• Improved tube performance
• Geographic expansion through local regulatory registrations
• Bundling with ophthalmic postoperative care products

A reformulated product should be priced against the total cost of use, including waste, contamination risk, administration difficulty, and pharmacy handling. A higher unit price is more defensible when the product reduces those costs.

What geographic markets offer the best opportunity?

The United States offers the clearest regulatory reference framework through the FDA, ANDA, 505(b)(2), and Orange Book systems. Other markets may offer opportunities where ophthalmic antibiotic ointments remain widely prescribed and local sterile manufacturing is limited.

Geographic expansion requires review of:

• National registration status
• Local requirements for fixed-dose combinations
• Antibiotic stewardship policies
• Prescription versus over-the-counter classification
• Local patent and supplementary protection rules
• Import and sterile manufacturing requirements
• Pharmacovigilance obligations
• Reimbursement and tender systems

The product’s active ingredients are globally familiar, but that does not ensure automatic approval. Fixed-dose combinations and legacy products can face country-specific documentation and quality requirements.

Key Takeaways

• NEO-POLYCIN is an anhydrous ophthalmic ointment containing bacitracin zinc, neomycin sulfate, and polymyxin B sulfate.
• Its labeled excipients are mineral oil and white petrolatum.[1]
• The core excipient platform supports ocular retention, sterility, and preservative-free formulation but can cause temporary visual blur and greasy residue.
• The strongest lifecycle opportunities are lower-blur delivery, unit-dose packaging, dose-control tubes, and improved extrusion performance.
• Biosimilar risk does not apply. Generic and private-label competition are the principal threats.
• Legacy active ingredients provide limited new patent leverage. Formulation, packaging, process, and manufacturing claims offer the more credible protection.
• A standard generic would likely create rapid price pressure. A differentiated 505(b)(2) product could support premium positioning if it demonstrates meaningful usability or performance benefits.
• Commercial expansion is most credible through sterile-manufacturing partnerships, private-label supply, institutional channels, and targeted geographic registrations.

FAQs

Is NEO-POLYCIN preservative-free?

The ointment formulation uses an anhydrous mineral oil and white petrolatum base and does not rely on an aqueous preservative system.[1]

Can NEO-POLYCIN be reformulated as an eye drop?

A conversion to an aqueous eye drop would be a substantial product change. It would require a new vehicle, solubilization or suspension strategy, sterility system, preservative assessment, dosing evaluation, and likely a different regulatory pathway.

What is the best excipient for reducing NEO-POLYCIN ocular blur?

No single excipient can be selected solely from the existing label. The most practical development strategy is to optimize mineral oil viscosity, petrolatum structure, particle dispersion, and delivered mass while measuring blur, residence time, and antimicrobial performance.

Could a unit-dose NEO-POLYCIN product obtain patent protection?

Yes, if the package or delivery system has novel, non-obvious characteristics tied to measurable benefits such as reduced contamination, controlled dose delivery, low residual volume, or improved sterility assurance.

Is NEO-POLYCIN suitable for biosimilar development?

No. NEO-POLYCIN is not a biologic. Competitive development would proceed through generic, 505(b)(2), private-label, or formulation-lifecycle pathways rather than biosimilar approval.

References

1. DailyMed. (n.d.). NEO-POLYCIN ophthalmic ointment: Bacitracin zinc, neomycin sulfate, and polymyxin B sulfate prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2023). Quality considerations for ophthalmic drug products. Center for Drug Evaluation and Research.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.